|
191 |
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Platelet Reactivity in Patients with Atherosclerotic Cardiovascular Disease: A Pooled Analysis of Two Randomized Double-blind Placebo-controlled Studies
Enthalten in Thrombosis and haemostasis 21.10.2025
|
|
|
|
192 |
Estimating Treatment Effect for Target Population in Psychiatric Clinical Trials Using Placebo Lead-in Design
Enthalten in Therapeutic innovation & regulatory science 19.10.2025: 1-16
|
|
|
|
193 |
Lactobacillus Paracasei CNCM I 1572 is Better than Placebo in Preventing Acute Diverticulitis Occurrence (Revised Manuscript 661a120f-b910-4133-ab7e-4bd3e1713c96)
Enthalten in Probiotics and Antimicrobial Proteins 17.10.2025: 1-8
|
|
|
|
194 |
A combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in healthy adults: a randomized, placebo-controlled phase 1 trial
Enthalten in Nature medicine 8.10.2025: 1-9
|
|
|
|
195 |
Effect of Oral Mirabegron on Catheter-Related Bladder Dysfunction After Elective Gynecological Surgery Under General Anesthesia: A Randomized, Placebo-Controlled, Double-Blind Study
Enthalten in International urogynecology journal 3.10.2025: 1-9
|
|
|
|
196 |
An Early Phase 2 Double-Blind, Placebo-Controlled Study of E6011, a Novel Anti-Fractalkine Antibody, in Patients with Crohn’s Disease
Enthalten in Inflammatory intestinal diseases Bd. 10, 2025, Nr. 1: 306-317. 12 S.
|
|
|
|
197 |
Comparative Efficacy of IL-12/23 and IL-23 Inhibitors for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: A Systematic Review and Network Meta-Analysis
Enthalten in Inflammatory intestinal diseases Bd. 10, 2025, Nr. 1: 265-284. 20 S.
|
|
|
|
198 |
Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial
Enthalten in Nature medicine 29.9.2025: 1-8
|
|
|
|
199 |
A double-blind, placebo-controlled investigation of the acute effects of Essence ring aromatherapy on sleep using actigraphy
Enthalten in Sleep and biological rhythms 26.9.2025: 1-10
|
|
|
|
200 |
Dupilumab Versus Mepolizumab for COPD: Evaluating Efficacy Outcomes Using Placebo-Adjusted Indirect Treatment Comparison
Enthalten in Pulmonary therapy 26.9.2025: 1-17
|
|
Administration
